Good afternoon :)
$
₹
Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

VRTX

NASDAQ
Asset Logo

Vertex Pharmaceuticals Inc

VRTX

NASDAQ
$546.182.11% (-11.77)
$
₹
$546.182.11% (-11.77)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $141.1B the stock is ranked 120

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

31.85
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

6.85
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$17.48
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.67
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

35%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 34 analysts' reports

Buy
18 analysts
Hold
14 analysts
Sell
2 analysts

Analysts expect a +4.29% price upside over the next year

Current Price$546.18
Target Price$569.53

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
—
—
P/E Ratio
73.51
73.51
—
—
1Y Return
23.04%
23.04%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
—
—
P/E Ratio
27.25
27.25
—
—
1Y Return
57.21%
57.21%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
—
—
P/E Ratio
—
—
—
—
1Y Return
34.82%
34.82%
Buy Reco %
63.33
63.33
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
—
—
P/E Ratio
20.36
20.36
—
—
1Y Return
46.1%
46.1%
Buy Reco %
76.00
76.00
argenx NV ADR
ARGX
argenx NV ADR
—
—
P/E Ratio
39.21
39.21
—
—
1Y Return
40.82%
40.82%
Buy Reco %
95.45
95.45

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Vertex Pharmaceuticals Inc 31.856.851.67
AbbVie Inc73.5150.450.36
Amgen Inc27.2520.262.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

3
1
3.2
1.1
2.9
1
3.3
1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue2.682.642.772.912.772.963.073.222.983.33
Net Income1.09-3.591.040.910.641.031.081.191.031.09
Net Profit Margin40.91%-135.83%37.71%31.35%23.33%34.83%35.20%36.90%34.53%32.98%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. Vertex Pharmaceuticals Inc (VRTX) share price today is $546.18 as of September 5, 2026 at 1:30 AM IST. The stock touched a day high of $557.07 and a day low of $544.66.

  2. Vertex Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol VRTX.

  3. Vertex Pharmaceuticals Inc's market capitalization is $141.11B as of September 5, 2026 at 1:30 AM IST.

  4. Vertex Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 31.85 as of September 4, 2026.

  5. Vertex Pharmaceuticals Inc's price-to-book (P/B) ratio is 6.85 as of September 4, 2026.

  6. Yes, You can buy Vertex Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Vertex Pharmaceuticals Inc shares in three steps: 1. Search Vertex Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Vertex Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Vertex Pharmaceuticals Inc (VRTX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0183 shares at the current price of $546.18.

Loading...